Ftse Mib
38.421,05
0,45%
DAX
22.287,56
-0,24%
S&P 500
6.013,13
-1,71%
NASDAQ
19.524,01
-2,20%
Bitcoin
96.522,03
0,40%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Xilio Therapeutics Inc (XLO) Xilio Therapeutics Inc (XLO) Notizie

Xilio Therapeutics Inc

XLO
0,915
-0,145 (-13,68%)
22 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
12/2/202513:36EDGAR2Form 8-K - Current report
12/2/202513:35GLOBEXilio Therapeutics Announces Multiple Masked T Cell Engager..
12/2/202513:33GLOBEAbbVie and Xilio Therapeutics Announce Collaboration and..
12/2/202513:30PRNUSAbbVie and Xilio Therapeutics Announce Collaboration and..
03/2/202522:30GLOBEXilio Therapeutics Announces Inducement Grants Under Nasdaq..
22/1/202515:00PRNCAOncology's Best Minds Set to Meet at Upcoming 2025 ASCO..
21/1/202523:09EDGAR2Form 8-K - Current report
21/1/202523:05GLOBEXilio Therapeutics Announces Initial Phase 2 Data for..
17/1/202522:30GLOBEXilio Therapeutics Announces Inducement Grant Under Nasdaq..
10/1/202523:00GLOBEXilio Therapeutics Announces Inducement Grant Under Nasdaq..
19/12/202413:45EDGAR2Form 8-K - Current report
19/12/202413:30GLOBEXilio Therapeutics to Present Initial Phase 2 Data for..
16/12/202413:30GLOBEXilio Therapeutics Appoints Caroline Hensley as Chief Legal..
03/12/202422:30GLOBEXilio Therapeutics Announces Inducement Grants Under Nasdaq..
07/11/202415:25EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202415:20EDGAR2Form 8-K - Current report
07/11/202415:15GLOBEXilio Therapeutics Announces Initial Clinical Trial Data..
07/11/202415:05GLOBEXilio Therapeutics Announces Pipeline and Business Updates..
30/10/202414:01GLOBEXilio Therapeutics to Present Initial Phase 1C Dose..
04/10/202415:05GLOBEXilio Therapeutics Announces Upcoming Poster Presentation at..
02/10/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202422:15GLOBEXilio Therapeutics Announces Inducement Grants Under Nasdaq..
28/9/202403:36EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
28/9/202403:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
13/9/202422:16EDGAR2Form 8-K - Current report
28/8/202422:01GLOBEXilio Therapeutics to Present at Morgan Stanley 22nd Annual..
08/8/202413:51EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202413:45EDGAR2Form 8-K - Current report
08/8/202413:30GLOBEXilio Therapeutics Announces Pipeline and Business Updates..
07/8/202402:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/6/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/6/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/6/202422:06EDGAR2Form 8-K - Current report
13/6/202422:15EDGAR2Form 8-K - Current report
13/6/202422:05GLOBEXilio Therapeutics Appoints Aoife Brennan, M.D., and James..
14/5/202414:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202413:45EDGAR2Form 8-K - Current report
14/5/202413:30GLOBEXilio Therapeutics Announces Pipeline and Business Updates..
01/4/202422:05GLOBEXilio Therapeutics Announces Pipeline and Business Updates..
28/3/202412:05GLOBEXilio Therapeutics Announces $11.3 Million Private Placement..
28/3/202412:00GLOBEGilead and Xilio Announce Exclusive License Agreement for..
28/2/202422:01GLOBEXilio Therapeutics to Participate in Novel Immuno-Oncology..
Apertura: 1,04 Min: 0,9184 Max: 1,06
Chiusura: 1,06

La tua Cronologia

NASDAQ
XLO
Xilio Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci